Study of MCLA-129 for advanced lung cancer with MET change
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called MCLA-129 for people with advanced non-small cell lung cancer that has a specific MET gene change (amplification) or who have previously been helped by a MET inhibitor. It is for those whose cancer has stopped responding to standard treatments like EGFR-targeted therapy or chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer that has spread or cannot be removed by surgery.
- You have tried at least one standard treatment (like targeted therapy or chemotherapy) and it no longer works or caused unbearable side effects.
- Your cancer has a MET gene change (called amplification), or you have taken a MET inhibitor drug that helped but then stopped working.
- You are generally up and about, with little or no help needed for daily activities.
- You have not taken a previous drug called an EGFR/c-Met bispecific antibody or a certain antibody-drug conjugate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
This trial tests a new combination treatment—MCLA-129 plus a targeted pill called Befotertinib—for people with advanced non-small cell lung cancer that has a specific EGFR gene change. It aims to see if the combination works better in patients who either haven't had treatment yet or whose cancer has stopped responding to other EGFR-targeted therapies.
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.